Cheaper Alternative to Jardiance (Empagliflozin)
Metformin is the most cost-effective alternative to Jardiance, with a median monthly cost of $2-5 compared to Jardiance's $448-569, while still providing excellent glycemic control and cardiovascular mortality benefits. 1, 2, 3
Cost Comparison
The price difference is dramatic:
- Metformin (generic): $2-5 per month for maximum approved doses 1, 2, 3
- Jardiance (empagliflozin) 25mg: $448-569 per month 1, 2, 3
- Other SGLT2 inhibitors: $543-574 per month (dapagliflozin, canagliflozin) 2, 3
This represents a 100-fold cost difference between metformin and Jardiance.
Clinical Efficacy Considerations
Metformin remains the first-line medication for type 2 diabetes management due to its high efficacy in lowering HbA1c, good safety profile, and extremely low cost 4, 5. It provides:
- HbA1c reduction of approximately 1-2%
- Minimal hypoglycemia risk when used as monotherapy
- Potential for modest weight loss
- Possible cardiovascular mortality benefit compared to sulfonylureas 4, 5
When Jardiance May Be Worth the Cost
You should prioritize Jardiance (or another SGLT2 inhibitor) over cost considerations if your patient has:
- Established cardiovascular disease - SGLT2 inhibitors reduce cardiovascular death by 38% and heart failure hospitalization by 35% 6, 7
- Heart failure - particularly with reduced ejection fraction 7
- Chronic kidney disease with albuminuria - SGLT2 inhibitors slow CKD progression by 39-40% 8, 7
- High cardiovascular risk (age ≥55 with coronary/carotid stenosis ≥50% or LVH) 3
In these specific populations, the cardiovascular and renal benefits of SGLT2 inhibitors justify their higher cost 6, 3, 7.
Alternative Lower-Cost Options Beyond Metformin
If metformin alone is insufficient and the patient doesn't have the above high-risk features:
Sulfonylureas (glimepiride, glipizide): $3-6 per month 2, 3
- Effective for glycemic control but cause weight gain and hypoglycemia
- Significantly cheaper than SGLT2 inhibitors
Pioglitazone (TZD): $4-5 per month 2, 3
- Reduces cardiovascular events in specific populations
- Causes weight gain, edema, and bone loss concerns
Important Caveats
Metformin contraindications include eGFR <30 mL/min/1.73 m² (absolute) and should be used cautiously with eGFR <45 8, 5. In these cases, SGLT2 inhibitors may be necessary despite cost.
Cost-effectiveness analyses show that while SGLT2 inhibitors are expensive upfront, they may reduce long-term complication costs in high-risk patients 9, 10, 11. The ICER for empagliflozin versus sitagliptin is approximately $7,000-12,000 per QALY gained, well below typical willingness-to-pay thresholds 11.